UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 403 - 411
METFORMIN | GLYCEMIC CONTROL | PLACEBO | MONOTHERAPY | SULFONYLUREA | SITAGLIPTIN | DOUBLE-BLIND | RANDOMIZED-TRIAL | POOLED ANALYSIS | MELLITUS | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glycosuria - chemically induced | Hypovolemia - chemically induced | Thiophenes - adverse effects | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Thiophenes - administration & dosage | Weight Loss - drug effects | Dose-Response Relationship, Drug | Glomerular Filtration Rate - drug effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Female | Blood Pressure - drug effects | Drug Therapy, Combination | Glucosides - adverse effects | Double-Blind Method | Insulin - administration & dosage | Treatment Outcome | Hypoglycemia - drug therapy | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin | Glucosides - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Mycoses - chemically induced | Clinical trials | Prescription drugs | Diabetes | Safety | Drug therapy | Index Medicus
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 09/2013, Volume 310, Issue 12, pp. 1240 - 1247
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Child, Preschool | Insulin - administration & dosage | Male | Treatment Outcome | Diabetes Mellitus, Type 1 - drug therapy | Blood Glucose - drug effects | Young Adult | Hypoglycemic Agents - administration & dosage | Adolescent | Adult | Female | Insulin Infusion Systems | Hypoglycemia - chemically induced | Child | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Diabetic Ketoacidosis - chemically induced | Therapy | Pumps | Clinical trials | Diabetes | Hypoglycemia | Insulin | Patients
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2019, Volume 381, Issue 21, pp. 1995 - 2008
NEPRILYSIN INHIBITION | OUTCOMES | COTRANSPORTER 2 INHIBITORS | MECHANISM | EMPAGLIFLOZIN | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycated Hemoglobin A - analysis | Humans | Middle Aged | Ventricular Dysfunction, Left - complications | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Drug Therapy, Combination | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Heart Failure - complications | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Kaplan-Meier Estimate | Stroke Volume - drug effects | Combined Modality Therapy | Hospitalization | Heart Failure - drug therapy | Cardiovascular Agents - therapeutic use | Diabetes Mellitus, Type 2 - blood | Ventricular Dysfunction, Left - drug therapy | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Measurement | Heart failure | Dapagliflozin | Patient outcomes | Physiological aspects | Cardiac output | Drug therapy | Testing | Intravenous administration | Renal function | Clinical trials | Hypoglycemia | Evidence-based medicine | Clinical outcomes | Sodium | Hemoglobin | Patient safety | Diabetes | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Ejection fraction | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Annals of internal medicine, ISSN 0003-4819, 06/2016, Volume 164, Issue 11, pp. 740 - 751
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Metformin - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Cause of Death | Metformin - adverse effects | Diabetes Mellitus, Type 2 - blood | Comparative Effectiveness Research | Diabetes Mellitus, Type 2 - mortality | Adult | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Hypoglycemic agents | Drug therapy | Comparative analysis | Patient safety | Prescription drugs | Diabetes | Hypoglycemia | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Diabetologia, ISSN 0012-186X, 12/2018, Volume 61, Issue 12, pp. 2461 - 2498
Heart failure | Costs | Weight management | Human Physiology | Patient-centred care | Glucose-lowering therapy | Hypoglycaemia | Metabolic Diseases | Internal Medicine | Cardiovascular disease | Chronic kidney disease | Type 2 diabetes mellitus | Guidelines | Medicine & Public Health | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | United States | Cardiovascular Diseases - drug therapy | Europe | Humans | Hyperglycemia - drug therapy | Consensus | Heart Failure - drug therapy | Renal Insufficiency, Chronic - drug therapy | Liraglutide - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Insulin - therapeutic use | Type 2 diabetes | Hyperglycemia | Chronic kidney failure | Cardiac patients | Self-care, Health | Glucose | Business education | Dextrose | Diabetes therapy | Glucagon | Diabetes mellitus | Body weight loss | Management | Coronary artery disease | Sodium | Arteriosclerosis | Patient-centered care | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Heart diseases | Glucagon-like peptide 1 | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 02/2016, Volume 39, Issue 2, pp. 222 - 230
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Body Weight - drug effects | Gastrointestinal Tract - drug effects | Male | Blood Glucose - drug effects | Liraglutide - adverse effects | Liraglutide - therapeutic use | Adolescent | Adult | Female | Renal Insufficiency - complications | Aged | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Hypoglycemia - chemically induced | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Usage | Care and treatment | Analysis | Clinical trials | Dosage and administration | Glycemic index | Hypoglycemia | Liraglutide | Risk factors | Kidney diseases | Diabetes | Medical treatment | Risk assessment | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 03/2016, Volume 39, Issue 3, pp. 353 - 362
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Canagliflozin - administration & dosage | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Metformin - therapeutic use | Double-Blind Method | Humans | Middle Aged | Male | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Hypoglycemic Agents - administration & dosage | Canagliflozin - therapeutic use | Adult | Female | Aged | Metformin - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Weight control | Blood pressure | Glucose | Diabetes | Hypoglycemia | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 384 - 393
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Purines - administration & dosage | Weight Loss - drug effects | Dose-Response Relationship, Drug | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Female | Quinazolines - administration & dosage | Linagliptin | Purines - adverse effects | Drug Therapy, Combination | Hypoglycemia - chemically induced | Glucosides - adverse effects | Double-Blind Method | Treatment Outcome | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Quinazolines - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Clinical trials | Care and treatment | Usage | Dosage and administration | Metformin | Diabetes | Safety | Drug therapy | Index Medicus
Journal Article